Blake Borgeson, an insider of Recursion Pharmaceuticals, Inc. (RXRX), reported a sale of Class A common stock that took place on July 7, 2026. The Form 4, filed July 9, disclosed the sale of 40,000 shares at a weighted average price of $3.9625 per share, for aggregate proceeds of approximately $158,500 before commissions or other costs. The transaction was reported as a sale of Class A common stock and was carried out under a Rule 10b5-1 trading plan that Borgeson adopted on August 31, 2025. Such plans allow insiders to schedule trades in advance under preset conditions, helping reduce concerns that a trade was made based on material nonpublic information. The filing notes that the sale was executed in multiple trades at prices ranging from $3.95 to $4.00 per share. The $3.9625 figure represents the weighted average sale price. Borgeson also undertook to provide detailed per-trade pricing information upon request to SEC staff, the company, or a Recursion security holder. No option exercise, vesting event, or equity award conversion was described in the filing text provided. The excerpt also does not state Borgeson’s beneficial ownership after the sale. The filing was signed on Borgeson’s behalf by Jonathan Golightly, attorney-in-fact, on July 9, 2026.